KalVista Q2 FY2025: No revenue, cash $135.8M; sebetralstat NDA accepted with PDUFA June 17, 2025

KalVista Pharmaceuticals, Inc.

2025-Q2 EPS reported -$1.78 revenue$50,000,000

R&D expenses $16.6M, G&A $29.2M; pro forma cash $292.2M after $156.4M net November raise.
FDA accepted NDA for oral on-demand HAE treatment sebetralstat; PDUFA date June 17, 2025.
MAA submissions in UK, Switzerland, Australia, Singapore via Access Consortium; EMA MAA validated in August.
Appointed Brian Piekos as CFO; raised $160M total via synthetic royalty financing and equity offerings.
New data presented at ACAAI and HAEi Global Angioedema Forum supporting early attack treatment and anxiety reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.